KOL Pulse

IMROZ - FREE ACCESS

The IMROZ trial has brought significant advancements in the treatment landscape for multiple myeloma, particularly for patients who are transplant-ineligible.

CARTITUDE-4

CARTITUDE-4 is a phase III, open-label, randomized trial of studying cilta-cel or standard care in lenalidomide-refractory multiple myeloma.

CARTITUDE-5

CARTITUDE-5 is a phase III study of bortezomib, lenalidomide and dexamethasone (VRd) followed by cilta-cel, vs. VRd followed by lenalidomide and dexamethasone (Rd) therapy in patients with newly diagnosed multiple myeloma for whom ASCT is not planned as initial therapy.

DREAMM-7

DREAMM-7 is a phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma.

IsKia

IsKia is a phase III randomized trial studying isatuximab-carfilzomib-lenalidomide-dexamethasone vs carflizomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients.

KARMMA-3

KARMMA-3 is an international, phase III, open-label, randomized clinical trial studying ide-cel or standard regimens in relapsed and refractory multiple myeloma.

PERSEUS

PERSEUS is a phase III, randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation (ASCT).